1. Liraglutide, semaglutide, and dulaglutide demonstrated similar kidney and cardiovascular protection in veterans with type 2 diabetes.
2. Liraglutide was associated with a lower all-cause mortality risk compared with both semaglutide and dulaglutide.
3. Dulaglutide showed a lower risk of gallstones and acute cholecystitis relative to semaglutide.
4. All three agents produced modest and comparable weight loss over 24 months (approximately 10–12 lb).
5. Findings support class-wide cardiorenal benefits while emphasizing individualized GLP-1RA selection based on patient-specific risks and comorbidities.

Sources:

JAMA Network Open Original Investigation

JAMA Network Open Invited Commentary